← brief for 2026-10-18 · Slowing decline
Shengjiang San attenuates diabetic kidney disease by suppressing renal NF-κB-mediated inflammation and rebalancing the Bax/Bcl-2 apoptotic axis: computational target prediction with in vivo and clinical validation
Key takeaways
This study looks at a traditional medicine for diabetic kidney disease. There is no abstract, so we do not have the results yet.
Who did this work
Xue Ru
Source
Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-10-17
https://doi.org/10.5281/zenodo.23429366